Photodynamic therapy for bladder carcinoma: today's medicine or tomorrow's horizon?

J. C. Picard; Werner T.W. de Riese; Brent A. Sharpe M.D.

doi:10.1117/12.432128

17 June 2002 Photodynamic therapy for bladder carcinoma: today's medicine or tomorrow's horizon?

J. C. Picard, Werner T.W. de Riese, Brent A. Sharpe M.D.

Proceedings Volume 4609, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XII; (2002) https://doi.org/10.1117/12.432128
Event: International Symposium on Biomedical Optics, 2002, San Jose, CA, United States

Abstract

Transitional cell carcinoma (TCC) of the bladder has a 40-70% local recurrence rate when treated with transurethral resection (TURBT)1 and carcinoma in situ (CIS) has a 54-83% recurrence rate within 4 years2. Today, the main therapy is intravesical chemotherapy, of which Bacillus Calmette-Guerin (BCG) is the most effective. However, because chemotherapy is only modestly beneficial3 and most bladder carcinomas will not respond to second course of BCG4, an additional treatment modality is being researched. Photodynamic therapy (PDT) combines a photosensitizing dye with laser therapy to destroy cancer cells. Pathologic cells take up the photosensitizing agent and upon activation by visible light (400 - 760 nm) the cancerous cells are destroyed. PDT can be used for focal or diffuse disease. It also can be used to treat recurrent and refractory superficial TCC, in addition to being used as a prophylactic measure. We review the literature (mostly retrospective or nonrandomized studies) that supports the use of PDT for TCC of the bladder. While PDT seems to be a very promising treatment modality, BGC intravesical treatment remains the standard of care for TCC. However if additional randomized trials confirm current data, PDT may soon be a recommendable option.

Citation Download Citation

J. C. Picard, Werner T.W. de Riese, and Brent A. Sharpe M.D. "Photodynamic therapy for bladder carcinoma: today's medicine or tomorrow's horizon?", Proc. SPIE 4609, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XII, (17 June 2002); https://doi.org/10.1117/12.432128

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available